Table 2. Cardiac endpoints.
| Characteristic | MoMHR (n = 35) | THA (n = 35) |
| Alcohol (units/week) | 14.6 (15.9) | 17.1 (14.7) |
| Smoking: (never/current/Ex.>5years/Ex.<5 years) | 22/4/2/7 | 23/3/1/8 |
| Treated or known hypertension | 6 | 11 |
| History of diabetes mellitus | 3 | 3 |
| Cholesterol (mmol/L) | 5.1±1.1 | 5.3±1.3 |
| Triglyceride (mmol/L) | 1.3±0.8 | 1.4±0.9 |
| High density lipoprotein cholesterol (mmol/L) | 1.2±0.4 | 1.2±0.4 |
| Low density lipoprotein cholesterol (mmol/L) | 3.3±0.9 | 3.4±1.1 |
| Total/high density lipoprotein cholesterol ratio | 4.4±1.4 | 4.6±1.7 |
| Statin treatment | 7 | 12 |
| History of ischaemic heart disease | 2 | 0 |
| NYHA cardiac failure score | 1 (1 to 1) | 1 (1 to 1) |
| Conduction defect identified by ECG | 3 | 2 |
| Resting heart rate | 63±12 | 62±9 |
| Left ventricular end-diastolic diameter (mm)** | 49±4 | 46±4 |
| End systolic diameter (mm) | 31±6 | 29±4 |
| Iinterventricular septum thickness(mm) | 11±2 | 11±2 |
| Posterior wall thickness (mm) | 11±1 | 10±2 |
| Ejection fraction (%)* | 60±9 | 65±7 |
Normally distributed data are presented as mean ±SD, and non-normally distributed data as median (IQR). Analysis is MoMHR versus THA. Continuous data were analyzed by paired t-test or Wilcoxon test; categorical data were analyzed by either Chi-squared test. *P<0.05, **P<0.01, P>0.05 for all other comparisons.